Evolution of treatment strategies for prostate cancer: a systematic review
DOI:
https://doi.org/10.56294/hl2024.575Keywords:
Cancer, prostate, treatmentAbstract
Introduction: Prostate cancer is one of the leading causes of morbidity and mortality in men, with prevalence and severity varying based on access to healthcare services and available treatment options. Objective: This systematic review aimed to explore the evolution of therapeutic strategies in the management of prostate cancer, evaluating the efficacy of different treatments and their impact on patients' quality of life. Methodology: A comprehensive search was conducted using Google Scholar, analyzing 22 selected articles after applying rigorous inclusion and exclusion criteria. Results: The findings indicate that androgen deprivation therapy, along with agents such as abiraterone and enzalutamide, has proven effective in managing hormone-sensitive and castration-resistant prostate cancer. Furthermore, second-generation antiandrogens and combination therapies with PARP inhibitors have demonstrated the ability to extend survival in specific cases. Conclusions: Immunotherapy, while showing limited benefits as a standalone treatment, exhibits greater efficacy when combined with other therapies, such as radiotherapy and chemotherapy. Nanomedicine remains an underdeveloped strategy but holds promise for enhancing the selectivity and efficacy of drugs in patients who have developed resistance to other treatments.
References
Agarwal, N., Azad, A. A., Carles, J., Fay, A. P., Matsubara, N., Heinrich, D., Szczylik, C., De Giorgi, U., Young Joung, J., Fong, P. C. C., Voog, E., Jones, R. J., Shore, N. D., Dunshee, C., Zschäbitz, S., Oldenburg, J., Lin, X., Healy, C. G., Di Santo, N., … Fizazi, K. (2023). Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet, 402(10398), 291–303. https://doi.org/10.1016/s0140-6736(23)01055-3
Belkahla, S., Nahvi, I., Biswas, S., Nahvi, I., & Ben Amor, N. (2022). Advances and development of prostate cancer, treatment, and strategies: A systemic review. Frontiers in Cell and Developmental Biology, 10. https://doi.org/10.3389/fcell.2022.991330
Borque-Fernando, A., Calleja-Hernández, M. A., Cózar-Olmo, J. M., Gómez-Iturriaga, A., Pérez-Fentes, D. A., Puente-Vázquez, J., Rodrigo-Aliaga, M., Unda, M., & Álvarez-Ossorio, J. L. (2023). Consenso multidisciplinar sobre idoneidad farmacológica en cáncer de próstata hormono-sensible metastásico. Actas urologicas espanolas, 47(2), 111–126. https://doi.org/10.1016/j.acuro.2022.12.004
Borque-Fernando, Á., Zapatero, A., Manneh, R., Alonso-Gordoa, T., Couñago, F., Domínguez-Esteban, M., López-Valcárcel, M., Rodríguez-Antolín, A., Sala-González, N., Sanmamed, N., & Maroto, P. (2024). Recomendaciones de tratamiento en el cáncer de próstata hormonosensible metastásico: selección de pacientes. Actas urologicas espanolas. https://doi.org/10.1016/j.acuro.2024.03.002
Bort Bueno, A. C., Sánchez Gómez, B., Mateos Gómez, P. A., Castro, A., Rodríguez Henche, N., & Díaz-Laviada Marturet, I. C. (2018). Nuevo activador de AMPK como agente antitumoral en cáncer de próstata. https://ebuah.uah.es/dspace/handle/10017/50641
Chen, Y., Zhou, Q., Hankey, W., Fang, X., & Yuan, F. (2022). Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death & Disease, 13(7), 1–11. https://doi.org/10.1038/s41419-022-05084-1
Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., Saad, M., Zurawski, B., Sakalo, V., Mason, G. E., Francis, P., Wang, G., Wu, D., Diorio, B., Lopez-Gitlitz, A., … on behalf of the MAGNITUDE Principal Investigators. (2023). Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 41(18), 3339–3351. https://doi.org/10.1200/jco.22.01649
Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N. D., Procopio, G., Guedes, J. D. C., Arslan, C., Mehra, N., Parnis, F., Brown, E., Schlürmann, F., Joung, J. Y., Sugimoto, M., Sartor, A. O., Liu, Y.-Z., Poehlein, C. H., Barker, L., del Rosario, P. M., & Saad, F. (2023). Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 41(6_suppl), LBA16–LBA16. https://doi.org/10.1200/jco.2023.41.6_suppl.lba16
Delgado, D. (2017). Cáncer de próstata: etiología, diagnóstico y tratamiento. Revista Médica de Costa Rica y Centroamérica, 620(73), 707-710. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=67715
Gómez-Veiga, F., Martínez-Breijo, S., Solsona-Narbón, E., Hernández, C., Ciudin, A., Ribal, M. J., Dickinson, L., Moore, C., Ahmed, H., Rodríguez Antolín, A., Breda, A., Gaya, J., Portela-Pereira, P., & Emberton, M. (2014). Terapia focal en cáncer de próstata. Alternativas de tratamiento. Actas urologicas espanolas, 38(7), 465–475. https://doi.org/10.1016/j.acuro.2013.12.006
Mulati, Y., Fan, Y., Yu, W., Zhang, Q., & He, Z. (2021). Novel androgen receptor inhibitors in non-metastatic, castration-resistant prostate cancer: A systematic review and network meta-analysis. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.733202
Organización Mundial de la Salud. (2020). Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer
Pérez Peralta, C. (2023). Eficacia de los nuevos antiandrógenos en el tratamiento del cáncer de próstata metastásico hormonosensible y en el cáncer de próstata resistente a castración metastásico. e_BUAH. Biblioteca digital Universidad de Alcalá.
Posdzich, P., Darr, C., Hilser, T., Wahl, M., Herrmann, K., Hadaschik, B., & Grünwald, V. (2023). Metastatic prostate cancer—A review of current treatment options and promising new approaches. Cancers, 15(2), 461. https://doi.org/10.3390/cancers15020461
Ramos, Juan, F. O., & Alejandro, M. C. (2018). Detección precoz de cáncer de próstata: Controversias y recomendaciones actuales. Revista médica Clínica Las Condes, 29(2), 128–135. https://doi.org/10.1016/j.rmclc.2018.02.013
Rastogi, I., Muralidhar, A., & McNeel, D. G. (2023). Vaccines as treatments for prostate cancer. Nature Reviews. Urology, 20(9), 544–559. https://doi.org/10.1038/s41585-023-00739-w
Savón Moiran, L. (2019). Cáncer de próstata: actualización. Revista Información Científica, 98(1), 117–126. http://scielo.sld.cu/scielo.php?pid=S1028-99332019000100117&script=sci_arttext
Silva, D., Abreu-Mendes, P., Mourato, C., Martins, D., Cruz, R., & Mendes, F. (2020). Cáncer de próstata, nuevas opciones de tratamiento: inmunoterapia. Actas urologicas espanolas, 44(7), 458–468. https://doi.org/10.1016/j.acuro.2020.01.009
Stankovic, M., Wolff, L., Wieder, T., Mendes, J., Schumacher, B., Barro-Bejarano, M., & Weber, C. (2023). La prostatectomía radical retropúbica abierta es todavía una técnica quirúrgica bien establecida para el tratamiento del cáncer de próstata. Actas urologicas espanolas, 47(3), 172–178. https://doi.org/10.1016/j.acuro.2022.09.004
Swami, U., McFarland, T. R., Nussenzveig, R., & Agarwal, N. (2020). Advanced prostate cancer: Treatment advances and future directions. Trends in Cancer, 6(8), 702–715. https://doi.org/10.1016/j.trecan.2020.04.010
Téllez-Bañuelos, M. C., Solorzano-Ibarra, F., Sierra-Díaz, E., Vázquez-Urrutia, J. R., Hernández-Flores, G., Bravo-Cuellar, A., González-Ochoa, S., & Ortiz-Lazareno, P. C. (2023). Inmunoterapia en cáncer de próstata: fundamentos y oportunidades para su aplicación en la clínica. Gaceta Mexicana de Oncología, 22(3), 130–139. https://doi.org/10.24875/j.gamo.23000123
Wang, I., Song, L., Wang, B. Y., Kalebasty, A. R., Uchio, E., & Zi, X. (2022). Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy. American Journal of Clinical and Experimental Urology, 10(4), 210. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428569/
Wasim, S., Park, J., Nam, S., & Kim, J. (2023). Review of current treatment intensification strategies for prostate cancer patients. Cancers, 15(23), 5615. https://doi.org/10.3390/cancers15235615
Deshmukh, R., Singh, V., Harwansh, R. K., Agrawal, R., Garg, A., Singh, S., Elossaily, G. M., Ansari, M. N., Ali, N., & Prajapati, B. G. (2024). Emerging trends of nanomedicines in the management of prostate cancer: Perspectives and potential applications. Pharmaceutics, 16(3), 297. https://doi.org/10.3390/pharmaceutics16030297.
Published
Issue
Section
License
Copyright (c) 2024 Judith Galarza, Daniel J. Alarcón, Isaac E. Intriago, Jeniffer M. Zambrano (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
